Serum Heparin-binding Epidermal Growth Factor-like Growth Factor (HB-EGF) as a Biomarker for Primary Ovarian Cancer

• Published in: Anticancer research 2017-07, Vol.37 (7), p.3955-3960
• Main Authors: Miyata, Kohei, Yotsumoto, Fusanori, Fukagawa, Satoshi, Kiyoshima, Chihiro, Ouk, Nam Sung, Urushiyama, Daichi, Ito, Tomohiro, Katsuda, Takahiro, Kurakazu, Masamitsu, Araki, Ryota, Sanui, Ayako, Miyahara, Daisuke, Murata, Masaharu, Shirota, Kyoko, Yagi, Hiroshi, Takono, Tadao, Kato, Kiyoko, Yaegashi, Nobuo, Akazawa, Kohei, Kuroki, Masahide, Yasunaga, Shin'ichiro, Miyamoto, Shingo
• Format: Article
• Language: English
• Subjects: Adult; Aged; Aged, 80 and over; Biomarkers, Tumor - blood; Disease Progression; Female; Gene Expression Regulation, Neoplastic; Heparin-binding EGF-like Growth Factor - blood; Humans; Middle Aged; Ovarian Neoplasms - metabolism; Ovarian Neoplasms - pathology; Prognosis; Survival Analysis; Up-Regulation
• ISSN: 0250-7005; 1791-7530
• DOI: 10.21873/anticanres.11779

Ovarian cancer is the most lethal malignancy among gynaecological cancers. Although many anticancer agents have been developed for the treatment of ovarian cancer, it continues to have an extremely poor prognosis. Heparin-binding epidermal growth factor-like grown factor (HB-EGF) has been reported to be a rational therapeutic target for ovarian cancer. Here, we evaluated the clinical significance of serum HB-EGF by examining the association between prognosis and serum HB-EGF levels in patients with primary ovarian cancer. We found that high serum HB-EGF concentrations were significantly associated with poor prognosis in a combined cohort of patients with all stages of ovarian cancer, as well as in a subset of patients with advanced disease. In addition, serum HB-EGF levels increased as the cancer advanced. These data suggest that serum HB-EGF may be a target for the design of novel therapies for ovarian cancer.